Novo Nordisk Built a Lilly-Killer. It Just Lost the Fight.
Novo Nordisk's next-gen obesity drug CagriSema was built to match Eli Lilly's tirzepatide. It failed a head-to-head Phase 3 trial, sending Novo's stock plunging and wiping out hundreds of billions in market value. The obesity drug throne just got a lot harder to reclaim.
Novo Nordisk spent years engineering what was supposed to be the ultimate weapon against Eli Lilly. A next-generation obesity drug that combined two appetite-crushing hormones into one weekly shot. A drug designed to dethrone Lilly's tirzepatide (sold as Mounjaro and Zepbound) as the king of weight loss.
Then Novo ran the head-to-head trial. And lost.
The Trial That Backfired
The study was called REDEFINE 4: a Phase 3, head-to-head showdown between Novo's CagriSema and Lilly's tirzepatide in adults with obesity. The goal wasn't even ambitious, honestly. Novo didn't need to beat tirzepatide. It just needed to prove CagriSema was "non-inferior," which is clinical-trial speak for "basically just as good."
It couldn't clear that bar.
After 84 weeks of treatment, patients on CagriSema lost 23.0% of their body weight. Impressive by any historical standard. But patients on tirzepatide lost 25.5%. When you zoom out to include everyone enrolled (not just those who stuck with treatment the whole time), the gap held: 20.2% for CagriSema versus 23.6% for tirzepatide. The difference was statistically significant, and non-inferiority was not demonstrated.
Think of it like a boxing match where you don't even need to win on the scorecards; you just need to avoid getting knocked out. CagriSema got knocked out.
$475 Billion in Smoke
The market's reaction was swift and brutal. Novo Nordisk shares plunged more than 16% in a single session. But this wasn't just a bad day at the office. It was the latest blow in a devastating decline that has now erased roughly $475 billion from the company's peak valuation above $650 billion in 2024.
To put that in perspective, Novo has essentially lost the entire market-cap premium it built during the Wegovy glory days. The stock is back to levels last seen around June 2021, before most people had ever heard the phrase "GLP-1."
BMO's Evan Seigerman was blunt, saying it's And Union Investment, a shareholder in both companies, said the trial
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
"challenging to pinpoint a reason why a patient would be prescribed CagriSema over Zepbound."
"clinically validated that Mounjaro outperforms CagriSema."
Worst-case scenario. That's the phrase multiple analysts used.
Why This Drug Was Supposed to Be Different
CagriSema isn't just semaglutide (the active ingredient in Wegovy and Ozempic) with a new label. It's a combination of two hormones: semaglutide, which targets the GLP-1 pathway to suppress appetite between meals, and cagrilintide, a long-acting amylin analogue that triggers fullness during meals.
The logic was elegant. Semaglutide makes you less hungry throughout the day. Cagrilintide makes you put the fork down sooner at dinner. Together, they attack overeating from two different angles, like a defensive scheme that covers both the run and the pass.
In earlier trials, the combination delivered. Phase 2 data showed 15.6% weight loss at 32 weeks, compared to 5.1% for semaglutide alone and 8.1% for cagrilintide alone. The additive effect was real. The problem? Lilly's tirzepatide, which targets GLP-1 and GIP receptors through its own dual mechanism, turned out to be even better.
Lilly's Stranglehold on Obesity
The REDEFINE 4 result doesn't just hurt CagriSema. It reinforces what the market has been slowly accepting: Lilly owns this category now.
Consider the numbers. In 2025, Lilly's tirzepatide franchise (Mounjaro plus Zepbound) generated roughly $36.5 billion in global sales, making it the world's best-selling medicine. Zepbound alone captured about 64% of U.S. branded anti-obesity prescriptions by Q4 2025, with nearly 70% of new prescriptions going to Lilly's drug.
Meanwhile, Lilly is guiding for $80 to $83 billion in total company revenue for 2026, a 25% jump. Novo? It warned that sales could decline by up to 13% this year. The trajectories couldn't be more different.
Wall Street is adjusting accordingly. Goldman Sachs slashed CagriSema's peak sales estimate from roughly $7.5 billion to $3 billion. Morgan Stanley upgraded Novo Nordisk from Underweight to Equal-weight. The consensus view is that CagriSema, once positioned as the successor to Wegovy and the answer to Lilly, is now a second-line option at best.
What Novo Does Next
Novo isn't giving up. It's planning a higher-dose Phase 3 trial in the second half of 2026, tripling the semaglutide component from 2.4 mg to 7.2 mg while keeping cagrilintide at 2.4 mg. Another study, REDEFINE 11, is expected in early 2027 to further test the drug's ceiling. And despite the head-to-head miss, CagriSema still produced 23% weight loss, which is strong enough to support a regulatory filing that's already underway.
But the strategic picture has shifted. Analysts now see Novo leaning on three survival plays: expanding Wegovy into cardiovascular and sleep apnea indications, accelerating its oral GLP-1 pill for the massive needle-averse population, and pursuing M&A outside core obesity to diversify earnings. Jefferies and others suggest the company may need to deploy $30 to $35 billion in deals.
The early-stage pipeline matters more than ever, too. Novo's amycretin (a next-generation multi-agonist) now carries the weight of the company's long-term obesity thesis. If it can't outperform tirzepatide where CagriSema failed, the "Novo catches up" narrative falls apart entirely.
The Bigger Picture: A Crowded Ring
The irony is that even Lilly can't rest easy. The obesity drug market is about to get a lot more crowded. Amgen's MariTide, an antibody-based GIP antagonist/GLP-1 agonist, is in Phase 3 with the promise of monthly or quarterly dosing. Viking Therapeutics is developing VK2735, a dual GLP-1/GIP agonist in both injectable and oral forms. Structure Therapeutics and AstraZeneca have oral GLP-1 pills in mid-stage trials.
Goldman Sachs projects that oral obesity pills could capture about 24% of the global weight-loss market (roughly $22 billion) by 2030. That's a massive shift from today's injection-dominated landscape.
For Novo, the path forward is narrower than it was a week ago. CagriSema was supposed to be the great equalizer. Instead, it confirmed what investors feared most: in a head-to-head fight with Lilly's best, Novo's best wasn't good enough.
Clinical & Regulatory5 min read
The FDA Just Gave Itself a Live Feed Into Clinical Trials
The FDA is getting a live data feed from two oncology trials run by AstraZeneca and Amgen, ditching the decades-old model of waiting months between data checkpoints. If it works, drug development timelines could shrink by years.
